Market survey to acquire expressions of interest for the supply of genomic prognostic and predictive testing of therapeutic response to chemotherapy in breast cancer care, named Oncotype DX Breast Recurrence Score test, or equivalent test under the rules of Annex II.5 of Legislative Decree 36/2023

Italy · Medical equipment & pharmaceuticals

different companies won awards here

1,670

of the awards went to the three most frequent winners

3%

winners of the last 12 months were new here

1,375 of 1,439

buyers awarded contracts here

389

Based on 2,607 awards with a named winner over the last 3 years. Counted by award, not by value, because lot and framework amounts are not comparable. Concentrated means the three most frequent winners took 65% or more of the awards; many suppliers, under 35% with at least ten different winners. New: no award from the same buyer or market in the two years before.

Competition

tenders per lot on average (open and restricted procedures)

1.9

of those lots received a single tender

38%

of the awards went to companies based in another country

1%

of the tenders came from another country

1%

As the official award notices state them, over the last 3 years. Tenders per lot count open and restricted procedures only: in a negotiated procedure or a direct award a single tender is the procedure itself. The country is the one the notice gives for the winner.